Olema Pharmaceuticals
OLMA
76 hedge funds and large institutions have $139M invested in Olema Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 14 increasing their positions, 32 reducing their positions, and 29 closing their positions.
126% more call options, than puts
Call options by funds: $480K | Put options by funds: $212K
5.38% less ownership
Funds ownership: 90.15% → 84.77% (-5.4%)
10% less capital invested
Capital invested by funds: $155M → $139M (-$16.2M)
16% less funds holding
Funds holding: 91 → 76 (-15)
41% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 29
56% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 32
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.77M |
| 2 |
NM
Newtyn Management
New York
|
+$1.59M |
| 3 |
LCM
Laurion Capital Management
New York
|
+$1.57M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.3M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$3.96M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.26M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
-$2.13M |
| 4 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
-$2.13M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$1.72M |
OLMA Hedge Fund Activity: Q2 2022 in Review
76 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Olema Pharmaceuticals (OLMA) for Q2 2022, worth a combined $139M — down 10% from $155M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of OLMA and 17 opened new positions — a net loss of 12 holders — while 32 trimmed existing stakes and 14 added.
The largest buyer was Millennium Management, adding an estimated $1.77M. The largest seller was BlackRock, cutting an estimated $3.96M.
- 76 institutional investors held Olema Pharmaceuticals (OLMA) as of Q2 2022, down from 91 in Q1 2022.
- Funds reported $139M of Olema Pharmaceuticals stock for Q2 2022, down 10% quarter-over-quarter.
- 17 funds opened new Olema Pharmaceuticals positions in Q2 2022 and 29 closed out, a net change of -12 holders.
- The largest Olema Pharmaceuticals buyer in Q2 2022 was Millennium Management, an estimated $1.77M added.
- The largest Olema Pharmaceuticals seller in Q2 2022 was BlackRock, an estimated $3.96M sold.
Based on aggregated 13F filings for Q2 2022.